What is claimed is:

1. An isolated antibody comprising a light chain variable region (VL) and a heavy chain variable region (VII), wherein the antibody binds to human FcRn; and wherein the VL comprises:

(i) a VL CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);

(ii) a VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15), and

(iii) a VL CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO: 12) or ASYAGSGIYV (SEQ ID NO: 13); and

the VH comprises:

(i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO: 22);

(ii) a VH CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO: 23): and

(iii) a VH CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO: 24).

2. The isolated antibody of claim 1, wherein the VL of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11.

3. The isolated antibody of claim 1, wherein the VH of the isolated antibody comprises the ammo acid sequence of SEQ ID NO: 9.

4. An isolated antibody comprising a light chain variable region (VL), a heavy chain variable region (VH), and a heavy chain constant region (CH), wherein the antibody binds to human FcRn; and wherein the VL comprises:

(i) a VL CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO: 14);

(ii) a VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO: 15): and

(iv) a VL CDR3 comprising the amino acid sequence CSYAGSGIYV

12. ~~Use of the~~The antibody of claim 1 or 4, ~~in manufacturing a medicament for modulating an FcRn activity~~for use in inhibiting binding of IgG to FcRn thereby treating an autoimmune or inflammatory disease or disorder characterized by the presence of inappropriately regulated IgG antibodies.

13. ~~Use of the~~The antibody of claim 1 or 4, for use in ~~manufacturing a medicament for~~ treating an autoimmune disorder or an inflammatory disorder ~~In~~ in a subject.

14. ~~Use of the~~The antibody of claim 1 or 4, for use in ~~manufacturing a medicament for~~ modulating the half life/levels of circulating IgG in a subject.

15. The antibody of claim 1 or 4, wherein the antibody binds human FcRn with a dissociation constant (KD) of less than 10 nM.

16. The antibody of claim 1 or 4, wherein the antibody is a human or humanized antibody or is non-immunogenic in a human.

17. The antibody of claim 1 or 4, wherein the antibody is chimeric.

18. The antibody of claim 1 or 4, wherein the antibody is selected from the group consisting of a Fab, a F(ab)'2, an Fv, and an scFv.

19. The antibody of any one of claims 12 to 14 wherein the autoimmune or inflammatory disease or disorder is selected from the group consisting of: Multiple Sclerosis, rheumatoid arthritis, inflammatory bowel diseases (IBD), lupus, ankylosing spondylitis, scleroderma, Sjogren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis, polymyalgia rheumatic, temporal arteritis /gian cell arteritis, alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatique syndrome

immune deficiency syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin disease, CREST Syndrome, Crohn's disease, Dego's disease, dermatomyositis, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Grave's disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes (Type I), juvenile arthritis, Meniere's disease, mixed connective tissue disease, myasthenia gravis, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, pemicious anemia, polyarteritis nodosa, polychondritis, polyglancular syndromes, polymyalgia rheumatic, polymyositis, dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, stiff-man syndrome, Takayasu arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo.

20. Use of the antibody of claim 1 or 4 in the manufacture of a medicament for treating an autoimmune or inflammatory disease or disorder, wherein the autoimmune or inflammatory disease or disorder is selected from the group consisting of: Multiple Sclerosis, rheumatoid arthritis, inflammatory bowel diseases (IBD), lupus, ankylosing spondylitis, scleroderma, Sjogren's syndrome, Goodpasture's syndrome, Wegener's granulomatosis, polymyalgia rheumatic, temporal arteritis /gian cell arteritis, alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatique syndrome immune deficiency syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin disease, CREST Syndrome, Crohn's disease, Dego's disease, dermatomyositis, juvenile dermatomyositis, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia, fibromyositis, Grave's disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, insulin dependent diabetes (Type I), juvenile arthritis, Meniere's disease, mixed connective tissue disease,

myasthenia gravis, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, pemicious anemia, polyarteritis nodosa, polychondritis, polyglancular syndromes, polymyalgia rheumatic, polymyositis, dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, stiff-man syndrome, Takayasu arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo.